Equities Analysts Set Expectations for BRAINSWAY LTD/S’s Q1 2019 Earnings (BWAY)

BRAINSWAY LTD/S (NASDAQ:BWAY) – Research analysts at Oppenheimer issued their Q1 2019 earnings per share estimates for shares of BRAINSWAY LTD/S in a note issued to investors on Monday, May 13th. Oppenheimer analyst S. Lichtman expects that the company will earn ($0.13) per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $17.00 price objective on the stock. Oppenheimer also issued estimates for BRAINSWAY LTD/S’s Q2 2019 earnings at ($0.12) EPS, Q3 2019 earnings at ($0.13) EPS, Q4 2019 earnings at ($0.14) EPS, FY2019 earnings at ($0.52) EPS, FY2020 earnings at ($0.40) EPS and FY2021 earnings at ($0.18) EPS.

Several other research analysts also recently weighed in on BWAY. Cantor Fitzgerald initiated coverage on BRAINSWAY LTD/S in a research note on Monday, May 13th. They issued an “overweight” rating and a $17.00 target price on the stock. LADENBURG THALM/SH SH initiated coverage on BRAINSWAY LTD/S in a research note on Monday, May 13th. They issued a “buy” rating and a $19.00 target price on the stock. Raymond James initiated coverage on BRAINSWAY LTD/S in a research note on Monday, May 13th. They issued an “outperform” rating and a $14.00 target price on the stock. Finally, CIBC initiated coverage on BRAINSWAY LTD/S in a research note on Monday, May 13th. They issued an “outperform” rating on the stock. Five analysts have rated the stock with a buy rating, BRAINSWAY LTD/S presently has a consensus rating of “Buy” and a consensus target price of $16.75.

NASDAQ:BWAY opened at $10.87 on Thursday. BRAINSWAY LTD/S has a 52-week low of $10.30 and a 52-week high of $12.39.

About BRAINSWAY LTD/S

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.

Featured Story: What is a Fibonacci Channel?

Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.